The osteoporosis treatment market is witnessing steady expansion as the prevalence of osteoporosis, fractures, and bone-related disorders increases among aging populations and postmenopausal women. Osteoporosis is a metabolic disease characterized by reduced bone mineral density, which can increase the risk of fractures affecting the hip, spine, forearm, and wrist. The condition is observed particularly among postmenopausal women, geriatric populations, and individuals with factors that can affect bone strength.

According to Fortune Business Insights, the global osteoporosis treatment market size was valued at USD 10.75 billion in 2018 and is projected to reach USD 19.68 billion by 2032, exhibiting a CAGR of 4.4% during the forecast period. North America dominated the osteoporosis treatment market with a market share of 43.91% in 2018. Increasing healthcare expenditure, growing awareness regarding available therapies, product development, and rising diagnosis rates are among the factors supporting market growth.

Osteoporosis treatment includes medicines and therapeutic approaches designed to address reduced bone strength and minimize the risk of fractures. The market encompasses several drug classes, including bisphosphonates, hormone replacement therapy, selective estrogen receptor modulators (SERMs), RANK ligand (RANKL) inhibitors, and other treatments. Bisphosphonates have traditionally represented an important treatment option because they help reduce bone loss by decreasing osteoclast activity and supporting bone strength and density. The market is also experiencing developments in drug delivery and diagnostic solutions. Manufacturers are exploring transdermal and microneedle patches to improve convenience and patient compliance. Fortune Business Insights highlights developments such as abaloparatide transdermal patch being developed by Teijin Pharma and a microneedle patch for teriparatide being developed by Zosano Pharma. Advanced diagnostic solutions, including Bindex, are also supporting faster and simpler osteoporosis screening and may contribute to higher diagnosis and treatment rates.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 & 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀:

Increasing prevalence of osteoporosis and related fractures is a major factor supporting demand for osteoporosis treatment. The condition is particularly associated with postmenopausal women, elderly populations, individuals with parathyroid hormone disorders, and men with a high risk of fractures. Fortune Business Insights notes that increasing awareness about osteoporosis and available treatment options is influencing treatment adoption worldwide.

New product launches are another important growth factor. The introduction of EVENITY by Amgen Inc. is highlighted as an example of an advanced therapy for severe osteoporosis. The product received approvals from the U.S. FDA, European Commission, and Japanese Ministry of Health, Labor and Welfare in 2019. Increased healthcare spending, research and development activities, pipeline development, and improved diagnostic solutions are also contributing to market expansion.

However, adverse effects associated with osteoporosis drugs, patent expirations, stringent regulatory requirements, delays in approvals, and product recalls can restrict market growth. Reported side effects mentioned by Fortune Business Insights include hot flashes, vomiting, leg cramps, changes in bowel activity, and diarrhea.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲:

The competitive landscape comprises companies with diversified product portfolios and ongoing product development activities. Amgen Inc. and Eli Lilly and Company are identified among the key players. Amgen's Prolia contributes significantly to its market position, while the company's EVENITY launch strengthened its osteoporosis treatment portfolio. Eli Lilly and Company is also a significant participant with its Forteo product and focus on osteoporosis drug development.

Other companies operating in the market include Novartis AG and F. Hoffmann-La Roche Ltd., which are focusing on product portfolio development and market penetration.

Top Companies In The Market

  • AbbVie Inc.
  • Eli Lilly and Company
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Sanofi
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Others

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀:

By Drug Class (Bisphosphonate, Hormone Replacement Therapy, Selective Estrogen Receptor Modulator (SERMs), RANK ligand (RANKL) Inhibitor, and Others)

By Route of Administration (Oral, and Parenteral)

By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Others)

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/osteoporosis-treatment-market-101034 

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀:

  • North America: The region dominated the market with a 43.91% share in 2018 and generated USD 4.72 billion in the same year. High disease incidence, healthcare expenditure, research and development activities, advanced drug delivery systems, and adoption of new treatments support regional growth.
  • Europe: Europe is expected to follow North America, supported by new drug launches and government initiatives. The European Commission's approval of EVENITY for severe osteoporosis in women is highlighted by Fortune Business Insights.
  • Asia Pacific: The region is expected to register the highest CAGR, driven by an increasing geriatric population, growing healthcare investments, adoption of new treatments, and rising osteoporosis awareness in countries such as China and India.
  • Latin America and Middle East & Africa: These markets are described as being at a nascent stage, with growth associated with improving healthcare infrastructure and increasing awareness.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗰𝗼𝗽𝗲:

The future of the osteoporosis treatment market is expected to be shaped by continued product development, increasing clinical trials, improved diagnostic solutions, and the introduction of alternative drug delivery systems. Growing R&D activities and pipeline analysis by market participants are expected to support the adoption of osteoporosis drugs. Increasing awareness, a growing geriatric population, rising healthcare expenditure, and demand for improved treatment options are also expected to influence the market through the forecast period.

Explore Japan’s Market Opportunities - Latest -Osteoporosis Treatment Market- Insights